Board of Directors
The following members make up the BioPharmX Board of Directors.
Chairman of the Board of Directors
Michael Hubbard served as a senior audit partner at Deloitte & Touche LLP from August 2007 until retiring in June 2014 and also at PricewaterhouseCoopers LLP from September 1986 to July 2007. In these roles, he served private and publicly held clients across the life sciences, waste management, construction, and technology sectors, advising domestic and international issuer companies on complex transactions, including 19 IPOs and numerous follow on equity and debt offerings. Mr. Hubbard holds a B.A. degree in Business Administration with a concentration in Accounting and an MBA degree from Washington State University. He is a licensed CPA in the states of Washington and California and is a certified practitioner of international financial reporting standards.
A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen marketing at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.
Stephen Morlock served as executive vice president and chief financial officer at Otis Spunkmeyer, Inc. from May 1994 until his retirement in June 2004. He also served as controller from August 1992 to April 1994. Prior to that, he held various management positions in accounting, financial planning, and internal audit at Westinghouse Electric Supply Company from November 1977 to July 1992. Since his retirement in June 2004, Mr. Morlock has not been active in any business activities. Mr. Morlock holds a B.S. degree in Accounting from San Diego State University.
Greg Vontz currently serves as chief executive officer at BlackThorn Therapeutics. Prior to that he served as chief executive officer and president at Topica Pharmaceuticals from August 2008 to December 2016. He also served as president, chief operating officer, and member of the board of directors at Connetics Corporation from 1999 to 2006. Prior to joining Connetics, Mr. Vontz spent 12 years at Genentech in various senior marketing and product development roles. Mr. Vontz is a graduate of the University of Florida and received a Masters in Business Administration from the Hass School of Business at the University of California at Berkeley.